Europe Oncology Biosimilars Market: By Drug Class, Granulocyte Colony Stimulating Factors and Hematopoietic Agents), By Cancer Type, By Indication, Neutropenia, and Non-Hodgkin's Lymphoma ) By Distribution Channel and Country
Europe Oncology Biosimilars Market size was valued at US$ 6,953.2 million in 2023 and is expected to grow at a CAGR of 19.2% during the forecast period 2024 to 2030. The European market provides a detailed overview of the Europe Oncology Biosimilars market, and that can be segmented by drug class, by cancer type, and by indication. By drug class, The Europe Oncology Biosimilars market has been segmented into Monoclonal Antibodies (mAb), Granulocyte Colony Stimulating Factors (G-CSF) and Hematopoietic Agents. The Monoclonal Antibodies (mAb) segment is likely to be the largest and fastest-growing segment in terms of drug class. Monoclonal antibodies and Insulin are seen to be the foremost segments regarding the growth rate during the forecast period because of extensive applications of monoclonal antibodies in the treatment of autoimmune disorders, cancer, and osteoporosis, and growing incidents of insulin dependent diabetes worldwide and growing demand for lucrative treatment options.
Based on the Cancer type, the Europe Oncology Biosimilars market is segmented into Blood Cancer, Breast Cancer and Others Among these, the Breast Cancer segment is expected to have a significant growing market during the forecast period 2022-2028. The accessibility of biosimilars in the field of oncology has dropped prices and made cancer treatment more accessible and affordable. Also, due to the increasing prevalence of cancer, healthcare systems around the world are focusing on dropping the burden of cancer by accepting cost effective treatment choices. Based on the Indication, the Europe Oncology Biosimilars market is segmented into Malignant Lymphoma or Multiple Myeloma, HER2 Positive Metastatic Breast Cancer (MBC), Neutropenia, and Non-Hodgkin's Lymphoma (NHL). The Metastatic Breast Cancer (MBC), segment accounts for the significant share in 2021. Based on the distribution channel, the Europe Oncology Biosimilars market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment accounts for the significant share in 2021.
In April 2021, Mylan (now Viatris) launched Abevmy a biosimilar for oncology In March 2021, mAbxience Research launched Alymsys, a biosimilar for various types of cancer
Germany, Italy, UK, France, Spain, Russia, and Poland market is expected to witness the highest market share during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Market Size in 2023 |
US$ 6,953.2 million |
|
By Drug Class |
|
|
By Cancer Type |
|
|
By Indication |
|
|
By Distribution Channel |
|
Download Free Sample Report
The Europe Oncology Biosimilars Market market size was valued at US$ 6,953.2 million in 2023 and is expected to grow at a CAGR of 19.2% during the forecast period 2024 to 2030.
The key players of are Europe oncology biosimilars market Sandoz International GmbH (Germany), Amgen Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), Samsung Bioepis (South Korea)
Europe Oncology Biosimilars market is driven by the cost-effectiveness and increasing demand for biosimilars
| 1.Executive Summary |
| 2. Europe Oncology Biosimilars Market Introduction |
| 2.1. Europe Oncology Biosimilars Market - Taxonomy |
| 2.2. Europe Oncology Biosimilars Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Cancer Type |
| 2.2.3.Indication |
| 2.2.4.Distribution Channel |
| 2.2.5.Country |
| 3. Europe Oncology Biosimilars Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Europe Oncology Biosimilars Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Europe Oncology Biosimilars Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Monoclonal Antibodies (mAb) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Granulocyte Colony Stimulating Factors (G-CSF) |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Hematopoietic Agents |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Europe Oncology Biosimilars Market By Cancer Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Blood Cancer |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Breast Cancer |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Europe Oncology Biosimilars Market By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Malignant Lymphoma or Multiple Myeloma |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. HER2 Positive Metastatic Breast Cancer (MBC) |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Neutropenia |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Non-Hodgkin's Lymphoma (NHL) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Europe Oncology Biosimilars Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Europe Oncology Biosimilars Market By Country, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Germany |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. France |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Italy |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. United Kingdom (UK) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Spain |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.Germany Europe Oncology Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Monoclonal Antibodies (mAb) |
| 10.1.2.Granulocyte Colony Stimulating Factors (G-CSF) |
| 10.1.3.Hematopoietic Agents |
| 10.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Blood Cancer |
| 10.2.2.Breast Cancer |
| 10.2.3.Others |
| 10.3. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Malignant Lymphoma or Multiple Myeloma |
| 10.3.2.HER2 Positive Metastatic Breast Cancer (MBC) |
| 10.3.3.Neutropenia |
| 10.3.4.Non-Hodgkin's Lymphoma (NHL) |
| 10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 11.France Europe Oncology Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Monoclonal Antibodies (mAb) |
| 11.1.2.Granulocyte Colony Stimulating Factors (G-CSF) |
| 11.1.3.Hematopoietic Agents |
| 11.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Blood Cancer |
| 11.2.2.Breast Cancer |
| 11.2.3.Others |
| 11.3. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Malignant Lymphoma or Multiple Myeloma |
| 11.3.2.HER2 Positive Metastatic Breast Cancer (MBC) |
| 11.3.3.Neutropenia |
| 11.3.4.Non-Hodgkin's Lymphoma (NHL) |
| 11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 12.Italy Europe Oncology Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Monoclonal Antibodies (mAb) |
| 12.1.2.Granulocyte Colony Stimulating Factors (G-CSF) |
| 12.1.3.Hematopoietic Agents |
| 12.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Blood Cancer |
| 12.2.2.Breast Cancer |
| 12.2.3.Others |
| 12.3. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Malignant Lymphoma or Multiple Myeloma |
| 12.3.2.HER2 Positive Metastatic Breast Cancer (MBC) |
| 12.3.3.Neutropenia |
| 12.3.4.Non-Hodgkin's Lymphoma (NHL) |
| 12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 13.United Kingdom (UK) Europe Oncology Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Monoclonal Antibodies (mAb) |
| 13.1.2.Granulocyte Colony Stimulating Factors (G-CSF) |
| 13.1.3.Hematopoietic Agents |
| 13.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Blood Cancer |
| 13.2.2.Breast Cancer |
| 13.2.3.Others |
| 13.3. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Malignant Lymphoma or Multiple Myeloma |
| 13.3.2.HER2 Positive Metastatic Breast Cancer (MBC) |
| 13.3.3.Neutropenia |
| 13.3.4.Non-Hodgkin's Lymphoma (NHL) |
| 13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 14.Spain Europe Oncology Biosimilars Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Monoclonal Antibodies (mAb) |
| 14.1.2.Granulocyte Colony Stimulating Factors (G-CSF) |
| 14.1.3.Hematopoietic Agents |
| 14.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Blood Cancer |
| 14.2.2.Breast Cancer |
| 14.2.3.Others |
| 14.3. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Malignant Lymphoma or Multiple Myeloma |
| 14.3.2.HER2 Positive Metastatic Breast Cancer (MBC) |
| 14.3.3.Neutropenia |
| 14.3.4.Non-Hodgkin's Lymphoma (NHL) |
| 14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Sandoz International GmbH |
| 15.2.2.Amgen Inc. |
| 15.2.3.Celltrion Healthcare Co., Ltd. |
| 15.2.4.Samsung Bioepis |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
